For example, in melanoma, combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy is the recommended treatment sequence, whereas in early stage NSCLC, atezolizumab is indicated following adjuvant platinum-based chemotherapy [123,125]. Here, MAP2K7 is linked to non-small cell lung carcinoma.